Jennifer Clarke MD

Jennifer Clarke MD

Associate Professor of Clinical Neurology and Neurological Surgery

Principal Investigator, Brain Tumor Research Center

Dr. Clarke specializes in novel approaches to the treatment of brain tumors in adult patients. As a member of the Brain Tumor Research Center, she is a co-investigator on single-institution clinical trials designed and run at UCSF, as well as multi-institution trials through the National Cancer Institute’s Adult Brain Tumor Consortium. In addition to the design of clinical trials, her research interests include novel imaging methods of characterizing tumors and their response to treatment. In particular, she is interested in the delineation of treatment effect from recurrent tumor and in the imaging of tumors in patients receiving anti-angiogenic agents. Other research interests include the evaluation of molecular methods of characterizing tumors and the assessment/improvement of quality of life in brain tumor patients. She also teaches and precepts neurology residents, introducing them to the subspecialty field of neuro-oncology.

Education, Training, and Previous Positions

1995: BS, California Institute of Technology (Caltech)
2001: MPH, University of California, Berkeley School of Public Health
2002: MD, University of California, San Francisco
2002-2003: Internship, Medicine, St. Mary's Medical Center, San Francisco
2003-2006: Resident, Department of Neurology, University of California, San Francisco
2006-2008: Fellow, Neuro-Oncology, Memorial Sloan-Kettering Cancer Center

Selected Professional Memberships and Appointments

American Academy of Neurology
Society for Neuro-Oncology
American Society of Clinical Oncology

Selected Honors and Awards

1991-1992: Millikan Scholar, Caltech
1993-1994: McLean Scholarship, Caltech
1994: Doris S. Perpall Speaking Award, Caltech
2000: University Fellowship, UC Berkeley
2001: UCSF Class of 1966 Scholarship
2003: Intern of the Year, St. Mary's Medical Center
2008: ASCO Foundation Merit Award

Selected Recent Publications

Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Apr 7. [Epub ahead of print] PubMed PMID: 25856113.

Barajas RF Jr, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Rep Radiol 2015;2015:731361.

Stathias V, Pastori C, Griffin TZ, Komotar R, Clarke J, Zhang M, Ayad NG. Identifying glioblastoma gene networks based on hypergeometric test analysis. PLoS One 2014;9(12):e115842.

Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol 2015;121(2):331-9.

Allen BK, Stathias V, Maloof ME, Vidovic D, Winterbottom EF, Capobianco AJ, Clarke J, Schurer S, Robbins DJ, Ayad NG. Epigenetic pathways and glioblastoma treatment: insights from signaling cascades. J Cell Biochem 2015;116(3):351-63.

Clarke JL. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma. Semin Radiat Oncol 2014;24(4):273-8.

Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS. Familial gliomas: cases in two pairs of brothers. J Neurooncol 2015;121(1):135-40.

Fogh S, Wahl M, Anwar M, Haas-Kogan D, Clarke JL, Sneed PK. Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas. Semin Radiat Oncol 2014;24(4):259-64.

Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol 2014;16(9):1255-62.

Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol 2014;16(7):984-90.

Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 2014;16(2):274-9.

Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol 2013;15(1):91-6.

Crane CA, Han SJ, Ahn BJ, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res 2013;19(1):205-14.

Nagpal S, Clarke JL. Neoplastic myelopathy. Semin Neurol 2012;32(2):137-45.

Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J 2012;18(1):26-31.

Clarke JL, Deangelis LM. Primary central nervous system lymphoma [review]. Handb Clin Neurol 2012;105:517-27.

Goldhoff P, Clarke J, Smirnov I, Berger MS, Prados MD, James CD, Perry A, Phillips JJ. Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. J Neuropathol Exp Neurol 2012;71(1):83-9.

Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012;7(2):382-5.

Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1;29(31):4175-80. Epub 2011 Oct 3. Erratum in: J Clin Oncol 2011;29(36):4847.

Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol 2011;13(12):1331-8.

Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery 2012;70(2):361-70.

Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD; North American Brain Tumor Consortium. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol 2011;13(10):1118-24.

Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol 2011;104(3):737-44.

Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 2011;114(6):1609-16.

Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010;67(3):279-83.

Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol 2010;12(3):274-82.

Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009;27(23):3861-7.

Chang SM, Nelson S, Vandenberg S, Cha S, Prados M, Butowski N, McDermott M, Parsa AT, Aghi M, Clarke J, Berger M. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol 2009;92(3):401-15.

Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging [review]. Curr Neurol Neurosci Rep 2009;9(3):241-6.

Clarke J, Abrey L, Karimi S, Lassman A. Psuedoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 2008;26(20 suppl; abstr 2025).
De Angelis L, Clarke J, Perez H. Retrospective analysis of patients with leptomeningeal disease (LMD) in the MRI era. J Clin Oncol 2008;26(20 suppl; abstr 2070).
Clarke J, Sul J, DeAngelis L, Lassman A, Hormigo A, Nolan C, Gavrilovic I, Gu B, Panageas K, Abrey L. A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM). Presented on November 15-18, 2007 at the 12th Annual Meeting of the Society for Neuro-Oncology, Dallas, TX.
Clarke J, Johnston SC, Bernstein R, Tong D, Hemphill III JC. External validation of the ICH score. Neurocrit Care 2004;1(1):53-60.